Cambridge Investment Research Advisors
TXMD icon

Cambridge Investment Research Advisors’s TherapeuticsMD TXMD Stock Holding History

Cambridge Investment Research Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-432
Closed -$8K – 3212
2022
Q1 		$8K Buy
432
+92
+27% +$1.45K ﹤0.01% 3149
2021
Q4 		$6K Buy
340
+32
+10% +$959 ﹤0.01% 3159
2021
Q3 		$11K Hold
308
– – ﹤0.01% 3072
2021
Q2 		$18K Buy
308
+21
+7% +$1.27K ﹤0.01% 3067
2021
Q1 		$19K Sell
287
-25
-8% -$1.96K ﹤0.01% 2846
2020
Q4 		$19K Buy
312
+16
+5% +$1.09K ﹤0.01% 2687
2020
Q3 		$23K Sell
296
-229
-44% -$18.3K ﹤0.01% 2485
2020
Q2 		$33K Sell
525
-20
-4% -$1.16K ﹤0.01% 2398
2020
Q1 		$29K Sell
545
-56
-9% -$5.55K ﹤0.01% 2219
2019
Q4 		$73K Sell
601
-78
-11% -$11.2K ﹤0.01% 2337
2019
Q3 		$123K Buy
679
+180
+36% +$25.4K ﹤0.01% 2212
2019
Q2 		$65K Buy
499
+156
+45% +$28K ﹤0.01% 2132
2019
Q1 		$84K Buy
+343
New +$90.8K ﹤0.01% 2199
2017
Q2 		– Sell
-249
Closed -$90K – 1984
2017
Q1 		$90K Buy
249
+14
+6% +$4.33K ﹤0.01% 1705
2016
Q4 		$68K Buy
+235
New +$72.8K ﹤0.01% 1611

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Cambridge Investment Research Advisors's TXMD Position: Q2 2022 in Review

Cambridge Investment Research Advisors sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 432 shares — an estimated $8K sold.

Cambridge Investment Research Advisors first reported a position in TXMD in Q4 2016 and held it in 15 quarters. The position peaked at $123K in Q3 2019. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Cambridge Investment Research Advisors reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 432 TherapeuticsMD shares in Q2 2022, an estimated $8K.
  • Cambridge Investment Research Advisors first reported a position in TherapeuticsMD in Q4 2016 and held it in 15 quarters.
  • Cambridge Investment Research Advisors's TherapeuticsMD position peaked at $123K in Q3 2019.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.